Source disclosure: February 05, 2026
Mitsubishi Chemical Group Corporation [4188.T]
TOKYO — Mitsubishi Chemical Group Corporation, listed on the Tokyo Stock Exchange under code number 4188, reported its third quarter earnings for the fiscal year ending March 2026 on February 5, 2026. The company's consolidated results for the period from April 1, 2025 to December 31, 2025, showed a decline in revenue and core operating income compared to the same period last year.
The company’s consolidated sales 2% decrease from the previous year. Core operating income dropped by 2.4%, standing at ¥185,622 million. Operating income fell significantly by 22.2% to ¥113,322 million. However, net profit attributable to owners of the parent increased substantially by 47.3% to ¥157,199 million. Basic earnings per share were ¥76.70, up from ¥41.72 in the corresponding period last year.
Notably, the company experienced a significant change in its business scope during this reporting period due to the transfer of shares and related assets of Mitsubishi Tanabe Pharma Corporation through absorption-type spin-off. This transaction was approved at the regular shareholders' meeting held on June 25, 2025, and completed as of July 1, 2025. As a result, the operations of Mitsubishi Tanabe Pharma Corporation and its subsidiaries have been classified as discontinued operations. Consequently, the figures provided exclude these non-operating entities, reflecting only the ongoing businesses.
Regarding dividends, the company maintained its quarterly dividend rate at ¥16.00 per share for the first and second quarters of the current fiscal year. For the third quarter, it is expected that the dividend will remain unchanged at ¥16.00 per share. No adjustments have been made to previously announced dividend forecasts.
Looking ahead, the company has revised its full-year forecast for the fiscal year ending March 2026. Sales revenue is now projected to be ¥3,672,000 million, representing a 7% drop from the prior year. Core operating income is anticipated to increase by 9.2% to ¥250,000 million, while operating income is expected to fall by 50.5% to ¥70,000 million. Net profit attributable to owners of the parent is forecasted to rise by 8.7% to ¥114,800 million. Basic earnings per share are estimated to be ¥34.29, indicating a modest growth of 4.4%.
These projections reflect various assumptions based on currently available information and reasonable estimates. Actual performance may vary due to numerous factors. Mitsubishi Chemical Group plans to disclose a reviewed interim report containing the review report after completing the voluntary review process, scheduled for release on February 12, 2026. Additionally, there have been minor adjustments to the 2025 fiscal year's actual performance data used in calculating the percentage changes in the full-year forecast, as noted in the document.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing